Standout Papers

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia 2014 2026 2018 2022 542
  1. A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia (2014)
    Dirk Blom, Tomas Hala et al. New England Journal of Medicine

Immediate Impact

3 by Nobel laureates 2 from Science/Nature 80 standout
Sub-graph 1 of 18

Citing Papers

Shining New Light on Biological Systems: Luminescent Transition Metal Complexes for Bioimaging and Biosensing Applications
2024 Standout
Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality
2023 Standout
7 intermediate papers

Works of Michael Lillestol being referenced

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
2014 Standout

Author Peers

Author Last Decade Papers Cites
Michael Lillestol 530 133 78 345 341 8 1.0k
Bettina S. Nedergaard 437 97 61 337 176 13 940
J. Betteridge 376 577 89 76 77 11 917
Luis Augusto Tavares Russo 339 95 51 690 964 22 1.4k
Ming‐yi Hu 261 45 81 580 745 22 1.2k
Vibeke R. Gerkins 140 311 34 302 250 9 1.2k
Michelle McNabb 154 237 119 497 596 6 1.3k
Wentao Wu 118 102 92 270 408 16 856
Peiqi Chen 306 50 19 703 953 29 1.3k
Sheryl L. Silfen 217 153 19 309 153 25 969
Zhousheng Xiao 115 60 52 261 78 12 964

All Works

Loading papers...

Rankless by CCL
2026